Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2003
Business Overview: A global developer and manufacturer of specialized scientific instruments for drug discovery research. The company operates through three primary channels: the Harvard Apparatus catalog, distribution partnerships (e.g., Amersham Biosciences), and a direct global sales force for high-value products.
Key Financial Metrics (Six Months Ended June 30, 2003)
| Metric | 2003 (in thousands) | 2002 (in thousands) |
|---|---|---|
| Total Revenues | $41,826 | $25,692 |
| Net Income | $1,521 | $1,791 |
| Operating Income | $3,341 | $2,667 |
| Cash from Operating Activities | $1,082 | $920 |
| Cash and Cash Equivalents (End of Period) | $9,186 | $27,025 |
| Total Debt (Current + Long-term) | $6,609 | $1,099 |
| Goodwill & Indefinite Intangibles | $34,623 | $31,140 |
Note: All figures are in thousands except per share data. Net income per share (diluted) was $0.05 for the six months ended June 30, 2003, compared to $0.07 in 2002.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 63% to $41.8 million, driven primarily by acquisitions (BTX and GeneMachines) which contributed approximately $16.3 million (39%) of total revenue. Organic revenue decreased slightly by approximately $200,000.
- Profitability: While operating income increased 25% to $3.3 million, net income declined 15% to $1.5 million. This decline was largely due to a one-time arbitration charge of approximately $815,000 related to the Union Biometrica acquisition and increased amortization of intangibles ($1.35 million vs. $0.61 million).
- Liquidity: Cash and cash equivalents decreased by $6.1 million to $9.2 million, primarily due to cash used for acquisitions ($12.7 million net cash outflow for acquisitions) and a $1.3 million settlement with Affymetrix.
- Debt: Total debt increased significantly due to a $6.0 million bridge loan secured in March 2003 to partially fund the GeneMachines acquisition.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management expects available cash, operating cash flow, and debt capacity to be sufficient to finance operations for at least the next twelve months. The company is negotiating a $25 million revolving credit facility to replace the current $6 million bridge loan. There is no specific quantitative revenue guidance provided for the full year.
Key Risks and Contingencies:
- Legal Proceedings:
- Union Biometrica: An arbitration award in favor of former shareholders resulted in a $815,000 charge and the release of escrowed shares. The award is pending final corrections.
- Affymetrix: Settled a dispute in June 2003 for $1.3 million.
- Grindle Arbitration: The company prevailed in an arbitration regarding the Harvard Apparatus acquisition; the court confirmed the decision in July 2003.
- Acquisition Integration: Risks associated with integrating Genomic Solutions, BTX, and GeneMachines, including potential disruption to operations and failure to realize anticipated synergies.
- Financing: Uncertainty regarding the terms of the new revolving credit facility; failure to close could force repayment of the bridge loan on unfavorable terms.
- Market Dependence: Significant exposure to the pharmaceutical and biotechnology industries, which face funding constraints and economic downturns.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating BTX and GeneMachines and whether they are meeting revenue projections.
- Debt Financing: Confirm the status and terms of the proposed $25 million revolving credit facility to ensure the $6 million bridge loan can be refinanced.
- Legal Resolutions: Monitor the finalization of the Union Biometrica arbitration award and any potential appeals.
- Organic Growth: Assess the trend of organic revenue, which showed a slight decline in the first half of 2003 despite overall growth.
- Intangible Assets: Review the valuation and amortization schedules for the significant increase in goodwill and intangible assets ($34.6 million).